Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus

Kim, Kyung‐Soo; Hong, Sangmo; Ahn, Hong‐Yup; Park, Cheol‐Young

doi:10.1007/s13300-020-00948-1

Cited by 9 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A randomized controlled trial (RCT) conducted by Kim et al on albuminuria in patients with type 2 diabetes concluded that lobeglitazone improved albuminuria in patients with type 2 diabetes as measured by the urinary albumin-creatinine ratio (UACR), and demonstrated it as beneficial. In the lobeglitazone treatment group, the new onset of microalbuminuria was reduced by 73%, the progression of albuminuria was reduced by 52%, and there was no significant difference with the pioglitazone treatment group [3].…”

Section: Albuminuriamentioning

confidence: 83%

See 1 more Smart Citation

Lobeglitazone and Its Therapeutic Benefits: A Review

2023

Cureus

View full text Add to dashboard Cite

Lobeglitazone is a newer oral hypoglycemic agent that has been tested in type 2 diabetes mellitus (T2DM). We aim to conduct a narrative review to find out the therapeutic benefits of lobeglitazone in patients with T2DM. We scientifically searched the electronic database of PubMed from inception until September 12, 2023, using Medical Subject Heading (MeSH) keywords. Additionally, we searched for pre-clinical trials related to lobeglitazone. We retrieved all available results of phase 1 to phase 3 studies of lobeglitazone in T2DM. Subsequently, we reviewed the results narratively. Three double-blind, randomized, placebocontrolled studies and a phase 3 trial of lobeglitazone showed that 0.5 mg daily dose exhibits effective therapeutic activity in glycemic, lipid, and hepatic control, and is also used as a secondary treatment in nonalcoholic fatty liver disease. Lobeglitazone exhibits as much antidiabetic activity as other thiazolidinediones such as pioglitazone and rosiglitazone. Side effects of lobeglitazone included peripheral edema, weight gain, and bone mineral density, which did not require hospitalization for these effects. This article highlights the pharmacological, pre-clinical, clinical, and safety pharmacology of novel thiazolidinedione lobeglitazone.

show abstract

Section: Albuminuriamentioning

confidence: 83%

“…Some Asian countries such as Korea and India have approved the use of lobeglitazone for the treatment of T2DM. It was invented and approved in Korea [3]. Pioglitazone has a positive impact on lipid profiles in T2DM patients.…”

Section: Introductionmentioning

confidence: 99%

Lobeglitazone and Its Therapeutic Benefits: A Review

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Along with its glucose‐lowering and lipid‐modifying effects, lobeglitazone has beneficial effects on beta‐cell function and survival 24‐26 . A recent study has shown that lobeglitazone may improve albuminuria in patients with T2DM 27 . Similar to other oral antidiabetic agents, lobeglitazone is effective as monotherapy and combination therapy 25,28,29 …”

Section: Introductionmentioning

confidence: 99%

“…[24][25][26] A recent study has shown that lobeglitazone may improve albuminuria in patients with T2DM. 27 Similar to other oral antidiabetic agents, lobeglitazone is effective as monotherapy and combination therapy. 25,28,29 In this study, we aimed to evaluate the efficacy and safety of lowdose (0.25 mg/day) lobeglitazone compared with standard-dose (0.5 mg/day) lobeglitazone in patients with T2DM and poor glucose control despite combination treatment with metformin and DPP4 inhibitor we often encounter in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study

Ryang

Kim

Bae

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aims To compare the efficacy and safety of adding low‐dose lobeglitazone (0.25 mg/day) or standard‐dose lobeglitazone (0.5 mg/day) to patients with type 2 diabetes mellitus (T2DM) with inadequate glucose control on metformin and dipeptidyl peptidase (DPP4) inhibitor therapy. Materials and Methods In this phase 4, multicentre, double‐blind, randomized controlled, non‐inferiority trial, patients with T2DM insufficiently controlled by metformin and DPP4 inhibitor combination therapy were randomized to receive either low‐dose or standard‐dose lobeglitazone. The primary endpoint was non‐inferiority of low‐dose lobeglitazone in terms of glycaemic control, expressed as the difference in mean glycated haemoglobin levels at week 24 relative to baseline values and compared with standard‐dose lobeglitazone, using 0.5% non‐inferiority margin. Results At week 24, the mean glycated haemoglobin levels were 6.87 ± 0.54% and 6.68 ± 0.46% in low‐dose and standard‐dose lobeglitazone groups, respectively (p = .031). The between‐group difference was 0.18% (95% confidence interval 0.017‐0.345), showing non‐inferiority of the low‐dose lobeglitazone. Mean body weight changes were significantly greater in the standard‐dose group (1.36 ± 2.23 kg) than in the low‐dose group (0.50 ± 1.85 kg) at week 24. The changes in HOMA‐IR, lipid profile and liver enzyme levels showed no significant difference between the groups. Overall treatment‐emergent adverse events (including weight gain, oedema and hypoglycaemia) occurred more frequently in the standard‐dose group. Conclusions Adding low‐dose lobeglitazone to metformin and DPP4 inhibitor combination resulted in a non‐inferior glucose‐lowering outcome and fewer adverse events compared with standard‐dose lobeglitazone. Therefore, low‐dose lobeglitazone might be one option for individualized strategy in patients with T2DM.

show abstract

The PPAR System in Diabetes

Ansquer

2023

Contemporary Diabetes

View full text Add to dashboard Cite

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus

Cited by 9 publications

References 42 publications

Lobeglitazone and Its Therapeutic Benefits: A Review

Lobeglitazone and Its Therapeutic Benefits: A Review

A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study

The PPAR System in Diabetes

Contact Info

Product

Resources

About